本帖最后由 老马 于 2012-1-13 21:20 编辑 : h2 n7 B, ]+ L" W
( j8 m4 u* A, f7 o$ n9 I; B" N' A爱必妥和阿瓦斯丁的比较. e4 S3 h" a7 x0 i' X: e
% N y# R! O+ v3 ^ k
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 ]3 M# g' e7 B m5 s5 }4 m( F0 u
; O" T* n9 y1 q- S/ b+ Y5 {
) y. X& a% K4 S! ]http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 U& b7 z9 k& K& k4 D- T
==================================================
- F. T n3 V/ d( B: M' tOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# w2 {. s. X6 N+ {# O* g9 IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 J8 s( _; d9 G/ ]3 l& uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- m9 s0 W; V1 a; Z
|